You are here

  • Home
  • Archive
  • Volume 7, Issue 3
  • Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series

Article info

Article menu

Download PDFPDF

Lupus
Clinical case
Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series

Authors

  • Theerada Assawasaksakul Division of Rheumatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand PubMed articlesGoogle scholar articles
  • Seelwan Sathitratanacheewin Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand PubMed articlesGoogle scholar articles
  • Preeyaporn Vichaiwattana Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand PubMed articlesGoogle scholar articles
  • Nasamon Wanlapakorn Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand PubMed articlesGoogle scholar articles
  • Yong Poovorawan Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, ThailandFRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit,Bangkok, Thailand PubMed articlesGoogle scholar articles
  • Wonngarm Kittanamongkolchai Mahachakri Sirindhorn Clinical Research Center, Faculty of Medicine, Chulalongkorn University, Bangkok, ThailandDivision of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, ThailandRenal Immunology and Transplantation Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Wonngarm Kittanamongkolchai; wonngarm.k{at}chulacrc.org
View Full Text

Citation

Assawasaksakul T, Sathitratanacheewin S, Vichaiwattana P, et al
Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
RMD Open 2021;7:e002019. doi: 10.1136/rmdopen-2021-002019

Publication history

  • Received October 14, 2021
  • Accepted November 9, 2021
  • First published December 3, 2021.
Online issue publication 
July 06, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.